Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30004261 | 1.00 | SYK (0.44) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL23147868 | 0.84 | SYK (0.43) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL29813534 | 0.84 | SYK (0.43) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL28695827 | 0.84 | CA12 (0.43) | SYKRORCNAMPTMAP4K4AAK1 | |
| SCHEMBL29813612 | 0.84 | SYK (0.45) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL15081332 | 0.84 | SYK (0.45) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL30398203 | 0.83 | AR (0.48) | SYKRORCNAMPTMAP4K4AR | |
| SCHEMBL29509761 | 0.83 | SYK (0.44) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL2015768 | 0.83 | SYK (0.44) | SYKRORCNAMPTMAP4K4EGLN2 | |
| SCHEMBL29178680 | 0.83 | SYK (0.44) | SYKRORCNAMPTMAP4K4EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117295717-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-115942972-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | SYK 3706/4885RORC 920/4885NAMPT 1039/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | SYK 3706/4885RORC 920/4885NAMPT 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.